{"id":4264,"date":"2025-08-27T17:01:50","date_gmt":"2025-08-27T14:01:50","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4264"},"modified":"2025-08-27T17:02:33","modified_gmt":"2025-08-27T14:02:33","slug":"astrazeneca-turkiye-ile-dicle-universitesi-hastanelerinden-klinik-arastirmalar-alaninda-yeni-is-birligi","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4264","title":{"rendered":"AstraZeneca T\u00fcrkiye ile Dicle \u00dcniversitesi Hastaneleri’nden Klinik Ara\u015ft\u0131rmalar Alan\u0131nda Yeni \u0130\u015f Birli\u011fi"},"content":{"rendered":"\n

2020 y\u0131l\u0131ndan bu yana T\u00fcrkiye\u2019de 2 milyar TL\u2019nin \u00fczerinde klinik ara\u015ft\u0131rma yat\u0131r\u0131m\u0131 yapan AstraZeneca T\u00fcrkiye, bu kapsamda Dicle \u00dcniversitesi Hastaneleri ile onkoloji, kardiyovask\u00fcler ve solunum yolu hastal\u0131klar\u0131 alan\u0131nda stratejik i\u015f birli\u011fini daha da g\u00fc\u00e7lendirme karar\u0131 ald\u0131. B\u00f6lgede klinik \u00e7al\u0131\u015fma say\u0131s\u0131n\u0131 art\u0131rmay\u0131, daha fazla hastaya ula\u015fmay\u0131, veri kalitesini y\u00fckseltmeyi ve s\u00fcre\u00e7leri h\u0131zland\u0131rmay\u0131 hedefleyen i\u015f birli\u011fi ile AstraZeneca T\u00fcrkiye\u2019nin bu hastanede y\u00fcr\u00fctece\u011fi klinik ara\u015ft\u0131rma say\u0131s\u0131n\u0131n 16’ya \u00e7\u0131kmas\u0131 da planlan\u0131yor.<\/strong><\/a> <\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

T\u00fcrkiye\u2019de en fazla say\u0131da klinik ara\u015ft\u0131rma y\u00fcr\u00fcten firmalar aras\u0131nda yer alan AstraZeneca T\u00fcrkiye, k\u00fcresel klinik ara\u015ft\u0131rma stratejisinde T\u00fcrkiye\u2019yi kritik bir \u00fclke olarak konumland\u0131r\u0131yor. 2020 y\u0131l\u0131ndan bu yana T\u00fcrkiye\u2019de 2 milyar TL\u2019nin \u00fczerinde klinik ara\u015ft\u0131rma yat\u0131r\u0131m\u0131 ger\u00e7ekle\u015ftiren \u015firket, bu \u00e7al\u0131\u015fmalar sayesinde hastalar\u0131n yenilik\u00e7i tedavilere erken eri\u015fimini sa\u011flarken ara\u015ft\u0131rma merkezlerindeki sa\u011fl\u0131k profesyonellerinin bilimsel ve teknolojik bilgi birikimini de art\u0131r\u0131yor.<\/p>\n\n\n\n

\u015eirket, bu \u00e7al\u0131\u015fmalar\u0131 kapsam\u0131nda son olarak Dicle \u00dcniversitesi Hastaneleri ile klinik ara\u015ft\u0131rmalar alan\u0131nda \u00f6nemli bir i\u015f birli\u011fine imza att\u0131. Bu stratejik ortakl\u0131k ile onkoloji, kardiyovask\u00fcler, solunum yolu hastal\u0131klar\u0131 klinik \u00e7al\u0131\u015fmalar\u0131 i\u00e7in fizibilite s\u00fcrecinden ba\u015flanarak klinik \u00e7al\u0131\u015fma say\u0131s\u0131n\u0131n art\u0131r\u0131lmas\u0131 ve daha fazla hastaya ula\u015f\u0131lmas\u0131 hedefleniyor. Di\u011fer yandan, hastane \u00e7al\u0131\u015fma ekibi ve saha koordinat\u00f6rlerinin e\u011fitimi ile bu alanda kaliteli veri olu\u015fturulmas\u0131 ve s\u00fcre\u00e7lerin iyile\u015ftirilerek klinik \u00e7al\u0131\u015fmalar\u0131n daha h\u0131zl\u0131 ba\u015flat\u0131lmas\u0131 da ama\u00e7lar aras\u0131nda yer al\u0131yor.<\/p>\n\n\n\n

T\u00fcrkiye genelinde 90\u2019\u0131n \u00fczerinde aktif klinik \u00e7al\u0131\u015fmas\u0131 bulunan AstraZeneca, yakla\u015f\u0131k 100 ki\u015filik klinik ara\u015ft\u0131rma ekibi ve 50 ki\u015filik medikal kadrosu ile Faz I, II ve III olmak \u00fczere klinik ara\u015ft\u0131rmalar\u0131n\u0131 s\u00fcrd\u00fcr\u00fcyor. Dicle \u00dcniversitesi Hastaneleri\u2019nde de 2023 y\u0131l\u0131ndan bug\u00fcne kadar 5 sorumlu ara\u015ft\u0131rmac\u0131n\u0131n g\u00f6rev ald\u0131\u011f\u0131 \u00e7al\u0131\u015fmalar kapsam\u0131nda 7\u2019si onkoloji, 5\u2019i solunum yolu hastal\u0131klar\u0131 olmak \u00fczere toplamda 12 klinik \u00e7al\u0131\u015fma ger\u00e7ekle\u015ftirildi. Bu s\u00fcre zarf\u0131nda 89 hasta taramas\u0131 yap\u0131ld\u0131 ve 64 hasta klinik ara\u015ft\u0131rma tedavilerine d\u00e2hil edildi. Anla\u015fma kapsam\u0131nda 2025 y\u0131l\u0131nda ise 3 yeni onkoloji ve 1 solunum yolu hastal\u0131\u011f\u0131 \u00e7al\u0131\u015fmas\u0131n\u0131n daha ba\u015flat\u0131lmas\u0131 planlan\u0131yor. Bu ara\u015ft\u0131rmalar ile birlikte AstraZeneca T\u00fcrkiye\u2019nin bu hastanede y\u00fcr\u00fctece\u011fi onkoloji ve solunum yolu hastal\u0131\u011f\u0131 klinik \u00e7al\u0131\u015fma say\u0131s\u0131 16 olacak.<\/p>\n\n\n\n

\u201cKlinik \u00e7al\u0131\u015fmalar\u0131n faydalar\u0131n\u0131 hastalar\u0131n ya\u015fam\u0131na yans\u0131tmak, sa\u011fl\u0131kta e\u015fitlik vizyonumuzun \u00f6nemli bir ad\u0131m\u0131\u201d<\/strong><\/strong><\/p>\n\n\n\n

\u0130\u015f birlikleri hakk\u0131nda konu\u015fan AstraZeneca T\u00fcrkiye Medikal Direkt\u00f6r\u00fc Dr. Deniz Ert\u00fcrk Erem<\/strong>, \u201cAstraZeneca olarak herkesin sa\u011fl\u0131kl\u0131 bir ya\u015fam s\u00fcrme ve sa\u011fl\u0131k hizmetlerine e\u015fit eri\u015fim hakk\u0131 oldu\u011funa inan\u0131yor, hastalar\u0131n ya\u015fam kalitesini art\u0131rmay\u0131 hedefliyoruz. Bu do\u011frultuda AR-GE ve klinik ara\u015ft\u0131rma stratejimiz de farkl\u0131 terapi alanlar\u0131na birden fazla y\u00f6nden m\u00fcdahale etmek, daha erken ve daha ak\u0131ll\u0131ca tedavi y\u00f6ntemleri geli\u015ftirmek ve d\u00f6n\u00fc\u015f\u00fcmsel teknolojilerle liderlik etmek \u00fczerine kuruludur. Dicle \u00dcniversitesi Hastaneleri ile ger\u00e7ekle\u015ftirdi\u011fimiz i\u015f birli\u011fi sayesinde kanser, solunum yolu hastal\u0131klar\u0131n\u0131 hedefleyen klinik alanda ara\u015ft\u0131rma say\u0131m\u0131z\u0131 art\u0131r\u0131rken kardiyovask\u00fcler hastal\u0131klar konusunda da yeni ara\u015ft\u0131rma f\u0131rsatlar\u0131n\u0131 de\u011ferlendirmeyi hedefliyoruz. B\u00f6ylece bu hastal\u0131klar\u0131n tedavileri i\u00e7in nitelikli ve g\u00fcvenilir veri \u00fcretimini, saha ekiplerinin yetkinli\u011fini geli\u015ftirme imk\u00e2n\u0131 da bulaca\u011f\u0131z. Bug\u00fcne kadar \u00fclkemizde \u00e7e\u015fitli payda\u015flar\u0131m\u0131zla birlikte y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz klinik ara\u015ft\u0131rmalarda edindi\u011fimiz deneyim, do\u011fru yap\u0131land\u0131r\u0131lm\u0131\u015f ortakl\u0131klar\u0131n hem hastalara yenilik\u00e7i tedavilere erken eri\u015fim sa\u011flad\u0131\u011f\u0131n\u0131 hem de ara\u015ft\u0131rma ekosistemini ileriye ta\u015f\u0131d\u0131\u011f\u0131n\u0131 net bi\u00e7imde bizlere g\u00f6sterdi. Bu i\u015f birli\u011fimizin de \u00fclkemizin klinik ara\u015ft\u0131rmalar alan\u0131ndaki kapasitesine g\u00fc\u00e7 kataca\u011f\u0131na inan\u0131yoruz. Bilimi oda\u011f\u0131m\u0131za alarak, hastalar\u0131m\u0131z\u0131n ya\u015fam kalitesini art\u0131racak ve sa\u011fl\u0131k sistemine kal\u0131c\u0131 de\u011fer katacak i\u015f birliklerimize devam edece\u011fiz.\u201d dedi.<\/p>\n\n\n\n

\u201cBilimin \u0131\u015f\u0131\u011f\u0131nda, en yeni tedavileri hastalar\u0131m\u0131za ula\u015ft\u0131rmaya kararl\u0131y\u0131z\u201d<\/strong><\/p>\n\n\n\n

Dicle \u00dcniversitesi Rekt\u00f6r\u00fc Prof. Dr. Kamuran Eronat<\/strong> ise a\u00e7\u0131klamas\u0131nda \u015funlar\u0131 s\u00f6yledi: \u201cDicle \u00dcniversitesi Hastaneleri olarak AstraZeneca T\u00fcrkiye ile imzalad\u0131\u011f\u0131m\u0131z bu i\u015f birli\u011fi protokol\u00fc, yaln\u0131zca \u00fcniversitemiz i\u00e7in de\u011fil, b\u00f6lgemiz ve \u00fclkemiz i\u00e7in de \u00e7ok b\u00fcy\u00fck bir ad\u0131md\u0131r. \u00d6zellikle onkoloji ve solunum yolu hastal\u0131klar\u0131 alan\u0131nda ger\u00e7ekle\u015ftirilecek klinik ara\u015ft\u0131rmalar hem bilimsel \u00fcretkenli\u011fimizi art\u0131racak hem de hastalar\u0131m\u0131za en g\u00fcncel ve en yenilik\u00e7i tedavileri ula\u015ft\u0131rmam\u0131zda bize g\u00fc\u00e7 verecektir. Bizler Dicle \u00dcniversitesi olarak her zaman bilimin ve insanl\u0131\u011f\u0131n hizmetindeyiz. Hastalar\u0131m\u0131z\u0131n en sa\u011fl\u0131kl\u0131, en modern ve en g\u00fcvenilir tedavilere eri\u015fmesi i\u00e7in sorumluluk al\u0131yoruz. Bu i\u015f birli\u011fi, b\u00f6lgemizdeki ve \u00fclkemizdeki binlerce hastaya umut olacakt\u0131r. Dicle \u00dcniversitesi, k\u00f6kl\u00fc akademik ge\u00e7mi\u015fi ve g\u00fc\u00e7l\u00fc bilim insanlar\u0131yla T\u00fcrkiye\u2019nin \u00f6nc\u00fc kurumlar\u0131ndan biridir. Bu anla\u015fma ile yaln\u0131zca klinik ara\u015ft\u0131rmalar\u0131n niteli\u011fini art\u0131rmakla kalm\u0131yor, ayn\u0131 zamanda Diyarbak\u0131r\u2019dan d\u00fcnyaya yay\u0131lan bir bilim ve sa\u011fl\u0131k k\u00f6pr\u00fcs\u00fc kuruyoruz. AstraZeneca T\u00fcrkiye ile birlikte att\u0131\u011f\u0131m\u0131z bu ad\u0131m, gelece\u011fin tedavi y\u00f6ntemlerini geli\u015ftirme yolunda \u00fclkemizi k\u00fcresel bilim sahnesinde daha da g\u00f6r\u00fcn\u00fcr k\u0131lacak ve en \u00f6nemlisi, insan hayat\u0131na dokunan kal\u0131c\u0131 faydalar sa\u011flayacakt\u0131r.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

2020 y\u0131l\u0131ndan bu yana T\u00fcrkiye\u2019de 2 milyar TL\u2019nin \u00fczerinde klinik ara\u015ft\u0131rma yat\u0131r\u0131m\u0131 yapan AstraZeneca T\u00fcrkiye, bu kapsamda Dicle \u00dcniversitesi Hastaneleri ile onkoloji, kardiyovask\u00fcler ve solunum yolu hastal\u0131klar\u0131 alan\u0131nda stratejik i\u015f birli\u011fini daha da g\u00fc\u00e7lendirme karar\u0131 ald\u0131. B\u00f6lgede klinik \u00e7al\u0131\u015fma say\u0131s\u0131n\u0131 art\u0131rmay\u0131, daha fazla hastaya ula\u015fmay\u0131, veri kalitesini y\u00fckseltmeyi ve s\u00fcre\u00e7leri h\u0131zland\u0131rmay\u0131 hedefleyen i\u015f birli\u011fi ile AstraZeneca T\u00fcrkiye\u2019nin bu hastanede y\u00fcr\u00fctece\u011fi klinik ara\u015ft\u0131rma say\u0131s\u0131n\u0131n 16\u2019ya \u00e7\u0131kmas\u0131 da planlan\u0131yor. <\/p>\n","protected":false},"author":1,"featured_media":4265,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4264"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4264"}],"version-history":[{"count":2,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4264\/revisions"}],"predecessor-version":[{"id":4269,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4264\/revisions\/4269"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4265"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}